Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression

Ítems similars

• Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
  per: Iwama, Eiji, et al.
  Publicat: (2014)
• Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR‐tyrosine kinase inhibitors
  per: Furuyama, Kazuto, et al.
  Publicat: (2013)
• Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
  per: Masuda, Chinami, et al.
  Publicat: (2017)
• Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR
  per: Iwama, Eiji, et al.
  Publicat: (2015)
• Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)
  per: Takeda Masayuki, et al.
  Publicat: (2012-08-01)